Cat. No.
MABL-3493
Application
depleting, FC
Isotype
Engineer antibody
Species Reactivity
Mouse
Clone No.
7D4
From
Recombinant Antibody
Specificity
7D4 recognizes mouse CD25 at an epitope comprising amino acid 184 to 194 (REHHRFLASEE). This epitope is distinct from the IL-2 binding site and does not block binding of IL-2 to CD25. Murine CD25 is a 55 kDa interleukin-2 receptor alpha chain (IL-2R alpha). CD25 is expressed by early progenitors of the T and B lineage as well as by activated mature T and B lymphocytes. By itself, CD25 binds IL-2 only with low affinity. However, CD25 associates with CD122 (IL-2 receptor beta chain) and CD132 (common gamma chain) to form the high affinity IL-2 receptor.
Alternative Names
IL-2-RA; Interleukin-2 receptor subunit alpha; IL-2 receptor subunit alpha; IL-2R subunit alpha; IL2-RA; p55
UniProt
P01590
Immunogen
The original rat IgM version of this antibody was raised by immunizing Lewis rats with HT2 cells in complete Freund's adjuvant via a intraperitoneal injection and subsequent generation of hybridomas.
Application Notes
7D4 is a non-IL-2 blocking anti-CD25 antibody that has been widely used to identify CD25-positive cells via flow cytometry (Kohyama et al., 2012; pmid: 22399592), for instance, to analyse Lymph node cells from BALB/c mice that were untreated or treated with 0.25 mg PC61 (Onizuka et al., 1999; pmid: 10397255) or to characterize brain-infiltrating immune cells (Maes et al., 2013). Although 7D4 does not inhibit IL-2 binding itself, it shows synergistic qualities with a cancer vaccine; namely, 7D4 with a cancer vaccine boosted the vaccine-induced anti-tumour response. Furthermore, this antibody was shown to be able to induce inactivation of regulatory T cells (Treg); the effect was particularly significant when this clone was used synergistically with another anti-CD25 clone - PC61 (Ab01107) (Kohm et al., 2006; pmid: 16517695; McNeill et al., 2007; pmid: 17212768). 7D4, when turned into a mouse IgG2a format, exhibits depleting qualities against Treg cells and can be used to remove Treg lymphocytes from the tumoral environment without blocking CD25 (IL-2 pathway) on T effector cells (Solomon et al., 2020). As a result, it can be utilized as a potential immunotherapy agent achieving Treg depletion without T effector cells' debilitation (Solomon et al., 2020).
Antibody First Published
Malek et al. Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex Proc Natl Acad Sci U S A. 1983 Sep;80(18):5694-8. doi: 10.1073/pnas.80.18.5694. PMID:6412230
Note on publication
Describes the generation and characterization of the antibody 7D4.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
